Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Globe Newswire•01/10/2026•16:05 ET
0
Key Highlights
- ➤AVERSA™ Fentanyl advances toward FDA IND filing and clinical studies (NTRB)
- ➤2021 offering warrants expired September 30, 2026, without extension or repricing (NTRB)
- ➤Nutriband (NTRB) enters sixth Nasdaq year with no debt and a cleaner capital structure
- ➤AVERSA™ Fentanyl commercial manufacturing scale-up completed in June 2025 (NTRB)
- ➤Nutriband (NTRB) plans patent application potentially extending AVERSA™ protection to 2046
Expert Statements
Gareth Sheridan, CEO of Nutriband Inc.
“That goal has not changed in five years: to change the world for the better by improving the safety standard of easily abused transdermal drugs, while making sure these safer treatments remain available to the patients who genuinely need them.”
Gareth Sheridan, CEO of Nutriband Inc.
“Looking ahead, our focus is firmly on advancing AVERSA™ Fentanyl toward an NDA filing.”
Gareth Sheridan, CEO of Nutriband Inc.
“Five years on, our commitment to shareholder value as our number one focus is unchanged, and as we move closer to commercialization of AVERSA™ Fentanyl, I have no doubt that strategy will continue to shine through.”
Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary
CEO letter reflects on five years of milestones since the Company's October 1, 2021 uplisting, as AVERSA™ Fentanyl advances toward an IND filing and the 2021 offering warrants expire as scheduled
Get started
Create a free account to read the full story.